Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), lung infiltration of Th2 cells, and high levels of IgE. To date, allergen-specific immunotherapy (SIT) is the only treatment that effectively alleviates clinical symptoms and has a long-term effect after termination. Unfortunately, SIT is unsuitable for plurisensitized patients, and highly immunogenic allergens cannot be used. To overcome these hurdles, we sought to induce regulatory CD4 þ T cells (T reg ) specific to an exogenous antigen that could be later activated as needed in vivo to control allergic responses. We have established an experimental approach in which mice tolerized to ovalbumin (OVA) were sensitized to the Leishmania homolog of receptors for activated c kinase (LACK) antigen, and subsequently challenged with aerosols of LACK alone or LACK and OVA together. Upon OVA administration, AHR and allergic airway responses were strongly reduced. OVA-induced suppression was mediated by CD25 þ T reg , required CTLA-4 and ICOS signaling and resulted in decreased numbers of migrating airway dendritic cells leading to a strong impairment in the proliferation of allergen-specific Th2 cells. Therefore, inducing T reg specific to a therapeutic antigen that could be further activated in vivo may represent a safe and novel curative approach for allergic asthma.
INTRODUCTION
Allergic diseases affect up to 30% of the population and their prevalence has steadily increased in recent decades. Among allergic diseases, asthma is a chronic inflammation of the lungs caused by an inappropriate immune response to a single or multiple airborne allergens. This pathology has a substantial economic burden for which the only targeted method of treatment is allergen-specific immunotherapy (SIT). SIT involves the administration by either subcutaneous injection or mucosal application of increasing doses of the allergen to which the patient is allergic. Unfortunately, this approach is ineffective for treating multi-sensitized patients, and despite recent clinical studies, numerous allergens are too immunogenic to be used in desensitization protocols. 1 SIT induces a state of peripheral tolerance characterized mainly by the generation of allergenspecific regulatory T cells (T reg ), along with the suppression of effector cell proliferation and cytokine production against the targeted allergen. 2, 3 Interleukin (IL)-10 and/or TGF-b producing T reg are the key factors for specific immunotherapy in humans. [4] [5] [6] It has been shown that treating naive (non-sensitized) mice with ovalbumin (OVA) aerosols results in the development of OVA-specific T reg and IgE unresponsiveness upon subsequent sensitization and challenge with OVA. 7, 8 Akbari et al. 8 have shown that lung draining lymph node (LN) dendritic cells (DCs) are able to create a local pro-regulatory environment by transiently producing IL-10 following a first contact with an inhaled antigen (Ag). These phenotypically mature DC induce the development of T reg , which in turn produces IL-10. 9 Respiratory tolerance can be achieved with only three intranasal (IN) administrations of Ag, which are sufficient to protect against airway hyperresponsiveness (AHR) and allergic inflammation upon further Ag sensitization and challenge. 10 TGF-bexpressing T reg also have a role in tolerance induction to inhaled Ags. 6, 11 In fact, SIT not only has been shown to alter the development of new sensitizations, but it has also been suggested that tolerance generated by SIT is not solely limited to the targeted allergen and also confers extended protection against other allergens. 12, 13 This non-specific and beneficial action of SIT could be explained by the activation of bystander T reg .
Bystander immunosuppression was first described by Bullock et al. 14 as a process in which Ag-specific T reg inhibit T effector cell responses directed to both the target Ag and to a colocalized third-party Ag. However, it was originally believed that in order for suppression to occur, the tolerogen and the Ag were required to be physically linked, i.e., presented by the same Ag-presenting cell (APC), at which point the terms linked suppression or linked recognition were coined. It was later shown that this state of induced tolerance was self-perpetuating and long lasting, and moreover, the tolerogen and the thirdparty Ag only needed to be in the vicinity of one another. [15] [16] [17] [18] In the field of oral tolerance, the term bystander suppression was introduced to describe inhibition of a T-cell memory response as a result of a regulatory response generated to an unrelated but colocalized tolerogen. 16, 19, 20 In bystander suppression, the tolerogen and third-party Ag do not need to be presented by the same APC. Admittedly, while soluble mediators are critical to induce suppression of the response directed to the third-party Ag, contact-based cell interactions are not excluded 19, [21] [22] [23] and have been recently demonstrated during graft tolerance. 24 In this study, we have investigated whether T reg specific for a third-party therapeutic Ag could control allergic immune responses and lung inflammation in mice. More specifically, we sought to demonstrate that therapeutic Ag-specific T reg could be recruited into the airway mucosa as needed during acute inflammatory bursts, and alter the natural development of allergic disease by modifying the microenvironment. To this aim, the Leishmania homolog of receptors for activated c kinase (LACK) Ag was used as an allergen model as described previously. 25, 26 Briefly, mice were sensitized to LACK, tolerized to OVA through three IN administrations as described previously, 8 and challenged with aerosols of LACK alone or with an additional OVA aerosol treatment to activate/recruit previously generated OVA-specific T reg .
RESULTS
Exposure to OVA aerosols inhibits LACK-induced allergic asthma in OVA-tolerized mice
To determine whether T reg specific for a third-party Ag could control allergic airway inflammation, mice were sensitized to LACK, tolerized to OVA through IN administrations, a protocol reported to induce respiratory tolerance via the induction of OVA-specific Treg, 9, 10 and tested for their ability to develop unresponsiveness to OVA upon further OVA immunization and challenge. When compared with phosphate-buffered saline (PBS)-treated mice, LACK-sensitized mice treated with OVA exhibited reduced AHR and airway allergic inflammation upon sensitization and challenge to OVA (Supplementary Figure 1 online) . In addition, OVA-treated mice also exhibited decreased OVA-specific IgE, further confirming that our treatment induced a state of tolerance to OVA (Supplementary Figure 1) . To investigate whether tolerance to OVA could improve asthma-related symptoms in mice sensitized and challenged to LACK, we sensitized mice to LACK and tolerized them to OVA and further challenged them with LACK aerosols alone (control) or both LACK and OVA to activate and recruit OVA-specific T reg to the airways ( Figure 1a) . When compared with the control group, mice treated with OVA aerosols showed decreased AHR (Figure 1b) , reduced numbers of total cells, eosinophils, and lymphocytes in the bronchoalveolar lavage fluids (BALFs) (Figure 1c) , and more specifically a reduced number of airway-infiltrating CD4 þ T cells expressing the Th2-marker T1/ST2 (IL-33Ra) (Figure 1d) . Concentrations of IL-4, IL-5, and IL-13 in the BALF were also decreased upon exposure to OVA during LACK challenges, while interferon (IFN)-g levels remained low and comparable in both groups (Figure 1e) . Interestingly, intracellular staining showed that OVA aerosols significantly decrease both the frequency and the number of IL-4, and IL-5-secreting LACK-specific CD4 þ T cells in comparison with mice that received LACK only aerosols (Figure 1f) . However, in our particular experimental settings, levels of LACK-specific IgE and IgG1 were not affected by OVA treatment (Figure 1g ). Since therapeutic administration of OVA was given during the LACK challenge phase, it was possible that the decreased amplitude of LACK-specific responses could be due to an artifact related to a suboptimal availability of LACK-loaded APCs. For this reason, we sensitized mice to LACK, omitted the OVA IN administrations, and challenged them with either LACK or both LACK/OVA aerosols (Supplementary Figure 2 ). Both groups exhibited similar AHR and BALF cellular infiltration, providing further evidence that the decrease in inflammation observed in the LACK/OVA-treated group was not due to diminished LACK-derived Ag presentation but rather to the induction of suppressive mechanisms (Supplementary Figure 2) .
To confirm our observations with a human relevant allergen, mice were tolerized to OVA, exposed to a series of ragweed (Ambrosia artemisiifolia) IN injections, and later administered an OVA IN analeptic (Figure 2a ). Similar to our previous results, mice treated with OVA at the later phase of ragweedinduced inflammation showed decreased AHR (Figure 2b) , reduced total numbers of cells, eosinophils, and lymphocytes in BALF (Figure 2c) , and a significant reduction in both the number and frequency of T1/ST2 þ CD4 þ T cells when compared with the control group, suggesting that ragweed-specific Th2 responses have been controlled (Figure 2d) . Likewise, BALF levels of IL-4 and IL-13 were also reduced upon later treatment with OVA, while IFN-g levels remained low and comparable in both groups (Figure 2e) . Altogether, our results suggested that OVA-induced tolerance could inhibit AHR, allergic airway inflammation and allergen-specific Th2 immune responses directed to another unrelated Ags.
Inhibition of LACK-induced airway inflammation in OVA-tolerized mice is mediated by OVA-specific CD25 þ T reg
Previous reports have shown that, in the absence of reporter mice, regulatory cells could be purified from the spleen of tolerized mice. 6, 26, 27 To investigate whether OVA-specific T reg were responsible for the suppression of LACK-induced airway inflammation, and whether this protection was Ag specific, 
total CD4
þ T cells were purified from the spleen of mice previously tolerized to OVA, or bovine serum albumin (BSA), or mock injection (PBS). Cells were injected into LACKsensitized recipient mice that were further treated with OVA aerosols alongside LACK challenges ( Figure 3a) . In contrast to the mice injected with CD4 þ T cells purified from BSA-tolerized or PBS-treated donors, mice injected with CD4 
Interestingly, CD4
þ T cells from OVA-tolerized mice were unable to transfer protection when depleted from the CD25-expressing cell subpopulation (Figure 3f-i) . However, adoptive transfer of purified CD25 þ CD4 þ T cells from OVA-tolerized mice provided similar levels of protection to that of the whole CD4 population (Figure 3f-i) . Taken together, these results suggest that not only does the inhibition of LACK-induced airway inflammation rely on the activation of CD25-expressing T reg , but also that in order for these cells to suppress LACKinduced inflammatory processes, they need to be reactivated and/or recruited with their Ag of specificity, i.e., OVA.
OVA-T reg depend on CTLA-4 and ICOS to control LACK-induced asthma
It is well documented that T reg mediate suppression through various mechanisms including the secretion of inhibitory cytokines, the induction of cytolysis, metabolic disruption, the inhibition of Ag presentation by DCs via CTLA-4-dependent mechanisms 28 and ICOS-ICOS-ligand interactions. 29 Consequently, we first sought to determine the role of CTLA-4 and ICOS in the inhibition of LACK-induced inflammation in our model. To this aim, LACK-sensitized OVA-tolerized mice were treated with CTLA-4, ICOS, blocking mAbs, or isotype control, during LACK/OVA challenge (Figure 4a) . Interestingly, inhibition of the T reg activation marker CTLA-4 restored AHR, airway cellular infiltration of eosinophils, lymphocytes, and T1/ST2 þ Th2 cells, along with the number of lung IL-4-and IL-5-producing LACK-specific CD4 þ T cells (Figure 4b-d) . Similar results were obtained by blocking ICOS/ICOSL signaling as shown by the restoration of AHR and comparable airway infiltration of eosinophils and lymphocytes to the LACK challenged group (Figure 4f, g ). Taken together, our results demonstrate that OVA-specific T reg control LACKinduced AHR and allergic airway inflammation in a CTLA-4 and ICOS-dependent mechanism. ) and brefeldin A (5 mg ml À 1 ). Data are expressed as mean ± s.e.m. of two experiments with n ¼ 8 mice per group. n.s., non-significant; *Po0.05; **Po0.01.
OVA-T reg inhibit LACK-specific Th2 cell proliferation and subsequent airway inflammation
To further understand the molecular mechanisms underpinning OVA-induced protection in this system, and more particularly the effects of OVA-T reg on LACK-specific responses, we sought to investigate the fate of LACK-specific Th2 effector cells. To this end, we modified our disease model and generated in vitro LACK-specific Th2 cells from Thy1.1 expressing LACK WT15 TCR transgenic RAG À / À mice. As described previously, CD4 þ T cells from the spleen of naïve WT15 mice were differentiated under Th2 polarizing conditions ( Supplementary Figure 3) , 25, 30 subsequently labeled with carboxyfluorescein succinimidyl ester (CFSE), and injected into OVA-or BSA-tolerized recipients before receiving a single ). Data show numbers of IL-4 and IL-5-secreting CD4 þ T cells in lungs. All data show either individual mice or are expressed as mean ± s.e.m., with n ¼ 5 mice per group pooled from two experiments. P-values have been calculated by comparing OVAtolerized mice with BSA-tolerized mice, n.s., non-significant; *Po0.05, **Po0.01, ***Po0.0001.
LACK þ OVA IN challenge (Figure 5a) . In this system, mice injected with LACK-specific Th2 cells that received an IN challenge displayed comparable inflammatory responses to the mice sensitized with LACK/Alum and challenged with aerosols used previously (Figure 5b-d) . When compared with the BSAtolerized group, mice treated with OVA IN and injected with LACK-specific Th2 cells exhibited decreased AHR (Figure 5b) , and reduced numbers of eosinophils and lymphocytes in the BALF (Figure 5c) . Interestingly, while no difference was observed in the blood, both the frequency and the number of donor LACK-specific Th2 cells were significantly reduced in the BALF, lung and mediastinal LN (MedLN) of OVA-tolerized mice when compared with BSA-tolerized mice (Figure 5d) . CFSE dilution profiles revealed that LACK-specific Th2 cells had undergone more divisions in BSA-tolerized mice than in OVA-tolerized mice (Figure 5e ), further suggesting that OVA-T reg inhibited LACK-specific Th2 cell proliferation. To address the ability of APCs to present LACK at the time of the challenge, ), and brefeldin A (5 mg ml À 1 ). Data are expressed as mean ± s.e.m. of three experiments with n ¼ 6 mice per group. Experimental groups were compared with untreated LACK-challenged mice. n.s., non-significant; *Po0.05; **Po0.01; ***Po0.0001.
cells from the MedLN and distal popliteal LN were purified 16 h after the LACK þ OVA IN challenge and incubated in vitro with naïve CFSE-labeled LACK-specific WT15 CD4 þ T cells to assess their ability to induce proliferation. As expected, popliteal LN cells did not promote cell division (Figure 5f ). However, LACK-specific T cells proliferated more vigorously when incubated with MedLN cells from BSA-tolerized mice than MedLN cells from OVA-tolerized mice (Figure 5f ).
Furthermore, to understand whether this phenomenon resulted from a quantitative (i.e., different number of LACK-loaded DCs in OVA-tolerized and BSA-tolerized mice) or qualitative defect (i.e., similar number of LACK-loaded DCs in OVA-tolerized and BSA-tolerized mice but different ability to induce T-cell proliferation), we administered PE-conjugated latex beads to OVA-and BSA-tolerized mice at the time of the challenge with LACK þ OVA, and the frequency of MedLN bead þ DCs was assessed 16 h later. While bead þ DCs were readily detected in the MedLN of both OVA-and BSA-tolerized mice and expressed similar levels of CD80, CD86, OX40L, and MHC class II molecules (not shown), the frequency of bead þ DCs was decreased from 4.7±0.7% in BSA-tolerized mice to 1.4±0.3% in OVA-tolerized animals ( Figure 5g) . Altogether, our data suggest that OVA-specific T reg inhibited the proliferation of LACK-specific Th2 cells by preventing the migration of airway DCs to MedLN.
DISCUSSION
Tolerance induction protocols, in the absence of adjuvant, accompanied with the generation of T reg cells have been reported using multiple distinct approaches. 6, 10, [31] [32] [33] [34] In this report, we have chosen to administer three IN injections with OVA to induce Ag-specific T reg . In contrast to chronic exposure to Ag aerosols, 7 this treatment does not confer a complete IgE unresponsiveness to further OVA sensitization and challenge (Supplementary Figure 1) , suggesting that the underlying mechanisms of suppression are qualitatively and/or quantitatively different. However, the suppression induced by these series of IN injections was previously described as an effective method to prevent graft rejection 32 but also as a way to suppress airway allergic inflammation. 10 In the present study, we have demonstrated that OVA-T reg generated following this approach are able to alleviate allergic symptoms induced by a different Ag upon their reactivation. We believe that these results represent an interesting therapeutic strategy; as such suppression would only be active upon local administration of the therapeutic Ag.
OVA-induced protection was not a result of Ag competition for the presentation of OVA or LACK, as non-tolerized mice challenged with both OVA and LACK displayed similar inflammatory responses as the LACK only challenged group. More importantly, experiments in which CD4 þ T cells were purified from the spleen of PBS-treated, BSA-or OVAtolerized mice and injected into LACK-sensitized recipients revealed that the suppression of inflammation was mediated by T reg that require their cognate Ag to be reactivated.
Inhibition studies showed that CTLA-4 was absolutely required for OVA-induced suppression of LACK-mediated allergic asthma. While we did not determine the role of CTLA-4 in our model, it has been shown to be critical for the suppressive ability of T reg cells both in vivo and in vitro.
35 CTLA-4 could prevent CD28 signaling in effector T cells (T eff ) by competing with CD80 and CD86, and/or to induce the synthesis of the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase by APCs, leading to T-cell suppression by both local depletion of tryptophan and induction of apoptosis via tryptophan catabolites. 35 While we were unable to detect increased apoptosis of LACK-specific T cells in OVA-tolerized mice upon challenge (not shown), we cannot rule out the possibility that this phenomenon was partially responsible for OVA-induced protection.
Blocking ICOS-ICOSL interactions induced the same effect as CTLA-4 inhibition. This result supports a previous study showing that ICOS À / À T reg did not confer protection upon transfer to asthmatic mice, demonstrating a crucial role of ICOS in their suppressive function. 29 Taken together, these data highlight the multiple and complex role of CD25 þ T reg . While these cells have been proposed to act via cell contact-dependent mechanisms in vitro, many more may also take part such as inhibitory cytokine production as well as non-cytokinedependent mechanisms in vivo depending on the experimental conditions. 36 Adoptive transfer of CFSE-labeled LACK-specific Th2 cells into OVA-tolerized recipient mice demonstrated that OVAspecific T reg significantly reduced the number of LACK-specific Th2 cells in the BALF, lung, and MedLN by affecting their proliferation. Additional experiments using of fluorescently labeled latex beads revealed that OVA treatment affected the migration of airway DCs into the MedLN, suggesting that one possible suppressive mechanism of OVA-T reg is their interaction with APCs to decrease the total load of Ag to reach the draining LNs, dampening therefore the amplitude of T eff response. These results are in agreement with the previous findings, which reported that airway T reg could decrease the expression of CD86 on DCs altering therefore their ability to migrate to the lung draining LNs. 37 While we did not characterize the state of activation of LACK-loaded DCs in our model, it is possible that OVA-T reg are using a similar approach, supporting further the crucial role of CTLA-4 in the protection against LACK-induced inflammation. However, it is important to notice that, while the effect on DCs could explain the decrease in proliferation of LACK-specific Th2 cells, it is also possible that OVA-T reg perform a second level of suppression in the MedLN by interacting directly with the T effector responses. Indeed, imaging data in mice have shown that T reg interact with DCs, altering the latter and diminishing subsequent DC-T eff cell conjugate formation in vivo. 38, 39 In addition, Derks et al. 40 have envisioned two hypotheses of APC function in bystander suppression: a passive APC model, in which the APCs would present MHC peptide to the T reg , stimulating them to produce immunosuppressive cytokines that would further binds their cognate receptors on the third-party T eff , or an active APC model, in which the APCs would propagate regulatory effects from the T reg to the T eff through various APC products. These two hypotheses remain to be tested in our model.
To eliminate the possibility of this protection being restricted to OVA protein, BSA-tolerized mice treated with BSA during the LACK challenge phase were equally protected from LACKinduced inflammation (data not shown). In conjunction with our findings with the human relevant allergen, ragweed, our data suggest that neither this protective phenomenon is restricted to the specific therapeutic Ag OVA, nor it is restricted to a specific allergen LACK.
Taken together, our results demonstrate that T reg specific for a third-party therapeutic Ag could control allergic immune responses and lung inflammation when re-stimulated in vivo. Our results may explain the protective effects of SIT against allergens that are different from those used during the desensitization treatment, also primary referred to as ''infectious tolerance'', as reported in several epidemiological studies. 12, 13, 41 In the same line of evidence, Campbell and his collaborators demonstrated the phenomenon of ''linked epitope suppression'' in which treatment with selected epitopes from a single allergen resulted in suppression of responses to other epitopes within the same molecule. They found that peptide treatment led to decreased proliferation and cytokine production to both treatment and non-treatment peptides. Using an experimental mouse model, they further showed that the IN administration of a single dose of peptide derived from the cat allergen Feld1 induced Ag-specific tolerance and resolution of allergic airway inflammation driven by exposure to whole cat allergen extract. While some questions remain to further understand the precise molecular and cellular mechanisms of such suppression, our study together with previous epidemiological and experimental evidence pave the way for the development of a novel curative approach that could control allergen-specific Th2 responses in patients with allergic asthma, and more specifically in patients sensitized to multiple allergens.
METHODS
Mice. Six-week-old BALB/c mice were purchased from The Centre d'Elevage Janvier (France) and housed under standard pathogen free conditions. LACK TCR transgenic mice (WT15 RAG-1 KO) on the BALB/c background as previously described 42 were bred in our animal facility at the Institut de Pharmacologie Moleculaire et Cellulaire (Valbonne, France). In this study, WT15 transgenic mice were further crossed onto RAG-1 À / À Thy1.1 þ / þ BALB/c mice. All experimental protocols were approved by the local animal ethic committee.
Reagents. LACK recombinant protein was produced in E. coli, purified as described previously, 43 and detoxified using an Endotrap column (Profos, Bernried am Starnberger See, Germany). Lipopolysaccharide contents in LACK protein were below 5 ng mg À 1 as determined using Limulus Amoebocyte Lysate (LAL) assay (Pierce, Illkirch, France). LACK 156-173 peptide was purchased from Mimotopes (Clayton, Victoria, Australia). T1/ST2 mAbs were purchased from MD Biosciences (St Paul, MN). Monoclonal antibodies to CD3, CD4, CD25, Thy1.1, CD11c, IA/IE, CD80, CD86, IL-4, and IL-5 were purchased from BD Biosciences (Le Pont de Claix, France).
Induction of allergic asthma and tolerization to OVA. Sensitization was performed by two intraperitoneal injections of 10 mg of LACK in 2 mg of Aluminium hydroxide (Alum) (Pierce) at days 0 and 7. On days 12, 13, and 14, mice were tolerized to OVA by injecting IN 100 mg of LPS-free OVA (Profos) as described previously. 8 From day 23 to day 27, mice were exposed either to LACK (0.15%) or to LACK plus OVA (0.2%) aerosols (administered 8 h apart) for 20 min using an ultrasonic nebulizer (Ultramed, Medicalia, Le Tholonet, France). Mice were analyzed on days 28 and 29 for AHR and airway inflammation, respectively. When indicated, mice were injected with either 0.5 mg of anti-CTLA-4 mAb (9H10) anti-ICOS (17G9) or isotype control (IgG1, GL113) every other day over the challenge period starting 1 day before the first aerosol. For ragweed-induced asthma, mice were first tolerized to OVA by receiving IN injections of OVA on days 0, 1, and 2 and further sensitized to ragweed via IN administrations of 25 mg ragweed (Greer Laboratories, Lenoir, NC) on days 11, 15, 19, and 23. Mice received a last challenge of ragweed on day 27 or ragweed and OVA on days 26 and 27. Mice were analyzed on day 28 for AHR and on day 29 for airway inflammation.
Th2 cell transfers. In some experiments, mice were first tolerized to OVA, BSA, or PBS and injected i.v on day 11 with LACK-specific CD4 þ Th2 cells. Mice were challenged 24 h later with a single IN injection of LACK (30 mg) and OVA (100 mg), and assessed for AHR, and immunological parameters 3 and 4 days later, respectively.
Airway hyperresponsiveness. For non-invasive measurements, mice were analyzed 1 day after the last aerosol challenge using whole body plethysmography as described previously. 44 Invasive measurements of dynamic lung resistance and compliance were performed 1 day after the last aerosol challenge using a Flexivent apparatus (SCIREQ, Emka Technologies, Paris, France) as previously described. 25 Briefly, mice were anesthetized (5 ml kg À 1 Dormitor 10% (Medetomidine, Pfizer, Paris, France)-Imalgene 10% (Ketamine, Merial, Lyon, France) tracheotomized, paralyzed (5 ml kg À 1 Pavulon 1% (Pancuronium bromide, Organon, Fresnes, France) and immediately intubated with an 18-G catheter, followed by mechanical ventilation. Respiratory frequency was set at 150 breaths per minute with a tidal volume of 0.2 ml, and a positive-end expiratory pressure of 2 ml H 2 O was applied. Increasing concentrations of methacholine (0-24 mg ml À 1 ) were administered at the rate of 20 puffs per 10 s, with each puff of aerosol delivery lasting 10 ms, via a nebulizer aerosol system with a 2.5-4 mm aerosol particle size generated by a nebulizer head (Aeroneb, Aerogen, Galway, France). Baseline resistance was restored before administering the subsequent doses of methacholine.
Analysis of BALF cells. Mice were bled and a canula was inserted into the trachea. Lungs were washed three times with 1 ml of warmed PBS. For differential BALF cell counts, cells were stained with mAb anti-CCR3 (R&D, Lille, France), anti-Gr1, anti-CD3, and anti-CD19 mAbs (Becton Dickinson, Le Pont de Claix, France) and analyzed by fluorescence in situ hybridization (FACS) using a FACScalibur flow cytometer (BD Bioscience) and Cellquest software (BD Bioscience). Eosinophils were defined as CCR3 þ CD3 À CD19 À , neutrophils as Gr-1 high CD3 À CD19 À , lymphocytes as CD3 þ CD19 þ , and alveolar macrophages as large autofluorescent cells.
Serum antibody measurements. Serum LACK-specific IgG1 and IgE were measured by ELISA. For IgG1 quantification, Ag-coated Maxisorp plates (Nunc, Illkirch, France) were incubated with serial dilution of sera and biotinylated anti-IgG1 mAb (BD). For Ag-specific IgE, plates were first coated with the respective capture mAb (BD), and incubated with serum dilutions. Biotinylated-LACK Ag was then added. HRP-conjugated streptavidin (BD) and TMB (KPL, Gaithersburg, MD) were used for detection.
Tissue processing. Lungs, LN, or spleens were cut into small pieces in HBSS containing 400 U type I collagenase and 1 mg ml À 1 DNAse I and digested for 30 min at 37 1C. Cells were strained through a 70-mm cell strainer. Erythrocytes were lysed with ACK lysis buffer.
Cytokine assays. Lung samples were homogenized in C 2 þ -and Mg 2 þ -free HBSS. BAL and lung supernatants were used. Multiplex IL-4, IL-5, IL-13, and IFN-g analysis was performed with CBA using FACS array (BD Biosciences). For intracellular staining, cells were incubated with 100 mg ml À 1 LACK and 1 mg ml À 1 of anti-CD28 (BD) for 6 h. Brefeldin A (5 mg ml À 1 , Sigma, Saint Quentin Fallavier, France) was added during the last 4 h. Cells were then stained with anti-CD4 mAb, fixed, permeabilized using cytofix/cytoperm reagent (BD), stained with anti-IL-4, or IL-5 (BD) and analyzed by FACS.
CD4
þ T-cell transfer. Donor mice were tolerized to OVA, BSA, or PBS as described above. Cells were prepared from spleens 21 days later, and CD4
þ T cells were enriched by negative depletion using CD4 isolation kit (Dynal, Illkirch, France) and further sorted using a highspeed sorter VANTAGE SETLO þ flow cytometer (BD) after staining with anti-CD3 and anti-CD4 mAbs. CD4 purity was 495%. In some experiments, enriched CD4 þ T cells were stained with antibodies to CD25, CD4, and CD3, and CD25
À and CD25 þ CD4 þ T-cell populations were sorted by FACS. Sorted cells were then injected i.v. into sensitized mice (4 Â 10 6 or 1.5 Â 10 6 cells per mouse, respectively) as described previously.
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Statistic analysis. ANOVA for repeated measures was used to determine the levels of difference between groups of mice for plethysmography measurements. Comparisons for all pairs were performed by Mann-Whitney U test. Significance levels were set at a Pvalue of 0.05.
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